Whales with a lot of money to spend have taken a noticeably bullish stance on Novavax.
Looking at options history for Novavax (NASDAQ:NVAX) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 80% of the investors opened trades with bullish expectations and 20% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $238,432 and 7, calls, for a total amount of $255,012.
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $7.5 to $17.5 for Novavax over the last 3 months.
Insights into Volume & Open Interest
In today's trading context, the average open interest for options of Novavax stands at 1732.0, with a total volume reaching 953.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Novavax, situated within the strike price corridor from $7.5 to $17.5, throughout the last 30 days.
Novavax Option Volume And Open Interest Over Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NVAX | PUT | SWEEP | BULLISH | 01/17/25 | $0.79 | $0.66 | $0.66 | $7.50 | $108.3K | 3.5K | 4 |
| NVAX | PUT | SWEEP | BEARISH | 07/12/24 | $2.27 | $1.98 | $2.02 | $15.00 | $72.9K | 27 | 0 |
| NVAX | PUT | SWEEP | BULLISH | 01/17/25 | $6.2 | $6.15 | $6.15 | $17.50 | $57.2K | 3.0K | 1 |
| NVAX | CALL | TRADE | BULLISH | 01/16/26 | $7.9 | $7.3 | $7.86 | $7.50 | $39.3K | 1.7K | 150 |
| NVAX | CALL | TRADE | BULLISH | 01/16/26 | $7.9 | $7.3 | $7.75 | $7.50 | $38.7K | 1.7K | 100 |
About Novavax
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
In light of the recent options history for Novavax, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Novavax's Current Market Status
- Trading volume stands at 5,226,531, with NVAX's price down by -7.32%, positioned at $12.97.
- RSI indicators show the stock to be is currently neutral between overbought and oversold.
- Earnings announcement expected in 41 days.
Professional Analyst Ratings for Novavax
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $18.0.
- Consistent in their evaluation, an analyst from B of A Securities keeps a Neutral rating on Novavax with a target price of $18.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novavax options trades with real-time alerts from Benzinga Pro.